Back to Agenda
Session 10: Special Regulatory Considerations for Development
Session Chair(s)
Elliott Berger, PHD, MS
President
ETB Regulatory Consulting, United States
- Special Protocol Assessment
- Special Development Pathways
- Expedited Programs for Serious Conditions
- Background and Subpart E
- Concepts for Expedited Programs
- Expedited Programs
- Fast Track
- Breakthrough Therapy Designation (BTD)
- Regenerative Medicine Advanced Therapy (RMAT)
- Accelerated Approval
- Qualified Infectious Disease Product (QIDP)
- Priority Review
- Orphan Products
- Priority Review Vouchers
Have an account?